J&J Targets $100B Revenue, Replimune Rebuffed Again and a “Revolution” In Pancreatic Cancer
Johnson & Johnson reported $24.1 billion in first‑quarter sales and set an ambitious $100 billion revenue target for 2026, underscoring its aggressive growth strategy amid a wave of biotech M&A. Replimune’s advanced melanoma therapy RP1 was denied again, with the FDA insisting on a Phase 3 trial the company deems unviable, highlighting the agency’s new policy of publishing complete response letters. Meanwhile, Revolution Medicines announced that its KRAS‑G12C inhibitor daraxonrasib doubled survival in a pancreatic cancer trial, a disease with a 13 % five‑year survival rate. The news comes as IPO activity heats up, exemplified by Kailera Therapeutics’ potential $533 million raise.
GlycoNex Secures Japan’s PMDA Approval for GNX1021 Phase I Trial
GlycoNex has secured approval from Japan’s Pharmaceuticals and Medical Devices Agency to launch a first‑in‑human Phase I study of its lead ADC, GNX1021, in advanced gastrointestinal cancers. The multi‑centre trial will begin patient enrollment in Japan by June 2026, with parallel IND...
Blood Test Predicts Kidney Failure Risk to Black Americans Years Before Onset
University of Pennsylvania researchers have unveiled a blood‑based test that predicts kidney‑failure risk in individuals of African ancestry carrying high‑risk APOL1 gene variants. The assay measures a small panel of circulating proteins to generate a ten‑year risk score, distinguishing patients...
A Molecular Movie Captures Cancer's Great Escape From Targeted Therapy
Researchers at the Institute for Systems Biology captured a "molecular movie" showing that melanoma cells enter a reversible, drug‑tolerant state within hours of BRAF‑targeted therapy. The study, published in Nature Communications, reveals an ordered two‑wave transcriptional program driven by NF‑κB‑mediated...
Scientists Turn AI-Generated Proteins Into Smart Molecular Sensors
An international team led by Queensland University of Technology used artificial intelligence to engineer tiny "smart" proteins that activate only when they bind a chosen molecule. Published in Nature Biotechnology, the AI‑designed switches produce color, light or electrical outputs, and...
No One’s Sure if Synthetic Mirror Life Will Kill Us All
In 2019 a group of synthetic biologists and ethicists convened to explore funding for “mirror” bacteria—microbes built from opposite‑handed proteins, sugars and lipids. By 2024, many participants warned that such organisms could evade natural predators and immune systems, potentially causing...
Can Europe Finance and Keep Its Biotech Winners?
The United States saw a surge of life‑sciences IPOs in early 2026, raising over $1 billion, while Europe continues to lose its biotech firms to foreign markets. Over the past six years, 66 of 67 EU biotech companies that went public...
Mending University and Venture Capital Relations: Is It Possible to See Eye-to-Eye?
European university spin‑outs in deep‑tech and life sciences now represent a $398 billion asset pool, but collaboration with venture capitalists remains fraught. Tech transfer offices are tasked with bridging divergent goals—academia’s focus on discovery and publications versus VCs’ demand for speed...
Partner Therapeutics Reports the US FDA sBLA Submission of Bizengri for NRG1 Fusion Positive Cholangiocarcinoma
Partner Therapeutics has filed a supplemental Biologics License Application (sBLA) with the U.S. FDA for Bizengri (zenocutuzumab‑zbco), a monoclonal antibody designed for adults with advanced unresectable or metastatic cholangiocarcinoma that carry an NRG1 gene fusion. The filing is supported by...
Toast-Time Trade-Off Eases as Gene-Edited Wheat Cuts Acrylamide Risk by 93%
Scientists at Rothamsted Research used CRISPR to edit wheat genes, slashing free asparagine levels by up to 93% and thereby reducing acrylamide formation in baked and fried foods. Field trials over two years showed the edited lines retained normal grain...
Could Biotech Layoffs Push Life Sciences Talent to Go Global?
Biotech firms are trimming staff amid a funding slowdown, but the layoffs are prompting a global reshuffling of life‑sciences talent. Major U.S. hubs like Boston see cuts, while the UK, Canada, France, Switzerland and Singapore roll out visa pathways and...
PreVenTB Trial: Considerations for Interpreting Extrapulmonary Tuberculosis Efficacy and Tuberculin Skin Test-Stratified Analyses
The PreVenTB phase‑3 trial evaluated the recombinant BCG vaccine VPM1002 and the subunit vaccine Immuvac in 12,700 Indian household contacts, but neither met the primary endpoint of preventing microbiologically confirmed tuberculosis. The authors noted a 23.1% versus 20.3% six‑month tuberculin...
Drug-Resistant Fungi Prompt a Five-Step Global Plan Ahead of WHO's 2026 Update
An international consortium of 50 researchers led by Radboudumc has issued a five‑step plan to curb the rise of drug‑resistant fungi. The strategy—covering awareness, surveillance, infection control, optimized drug use, and investment—aims to shape the World Health Organization’s 2026 Global...
Deep Dive: Checking in with the FDA
The FDA’s 2025 turmoil included a 3,500‑person workforce cut, multiple leadership turnovers, and a surge in guidance reversals that delayed drug reviews. In 2026, the agency declined to file Moderna’s mRNA‑1010 flu vaccine, contradicting earlier guidance, underscoring regulatory uncertainty. Despite...
Study Identifies New Genes Linked to Severe Pregnancy Sickness
USC researchers expanded the genetic landscape of hyperemesis gravidarum, identifying nine additional genes alongside the previously known GDF15, GFRAL, IGFBP7, and PGR. The genome‑wide association study analyzed 10,974 HG cases and 461,461 controls across diverse ancestries, the largest cohort to...
Remembering Sofinnova’s Denis Lucquin, Father of French Biotech
Denis Lucquin, a founding partner of Sofinnova Partners and a pivotal architect of France’s biotech sector, died on April 3 at age 69 from pancreatic cancer. Over three decades he invested in 31 European biotech companies, including Ablynx, Nicox and Novexel, and...
MicroRNA Signature Predicts Localized Clear Cell RCC
A new commentary in the British Journal of Cancer re‑examines the Bio‑miR study, which proposed a microRNA signature to predict outcomes in localized clear cell renal cell carcinoma (ccRCC). The authors highlight statistical and reproducibility concerns, showing that several miRNA...
Differentiated SH-SY5Y Cells Show Neuronal Traits, Immature Synapses
Researchers published a study showing differentiated SH‑S5Y cells express neuronal markers but fail to develop mature synaptic machinery, limiting their utility for synaptic physiology and drug screening. Using imaging, electrophysiology and transcriptomics they demonstrated absent synaptic currents and down‑regulated synapse...
Turkish PDQoL-7 Validated for Older Adults
Turkish researchers have validated a version of the Parkinson’s Disease Quality of Life‑7 (PDQoL‑7) scale specifically for older adults, publishing the findings in BMC Geriatrics. The validation demonstrated strong reliability, internal consistency, and construct and criterion validity using factor analysis...
GLP-1 Goes For The Middle
Indian pharmaceutical firms are rapidly converting the GLP‑1 hype into scale after Novo Nordisk’s semaglutide patent expired in March. Generics from Sun Pharma, Torrent, Zydus and others have already captured more than 15% of the market, pushing Novo’s share down...
Genome-Wide Tandem Repeat Expansions Modify Schizophrenia Risk in the Presence of a 22q11.2 Deletion
Researchers sequenced the genomes of 438 individuals with the 22q11.2 deletion and discovered that rare tandem repeat expansions (TREs) are significantly enriched in those who develop schizophrenia. The burden of genic TREs showed odds ratios of 1.75–2.14, comparable to the...
Traws Pharma Inc (TRAW) Q4 2025 Earnings Call Transcript
Harrow Health reported Q4 2025 revenue of $89.1 million, a 33% year‑over‑year increase, and full‑year revenue of $272 million, up 36%. Management forecast 2026 revenue between $350 million and $365 million, with adjusted EBITDA of $80‑100 million, driven by sales‑force...
Editorial Expression of Concern: Creation of Human Tumour Cells with Defined Genetic Elements
Nature issued an editorial expression of concern on April 15, 2026 for the 2022 paper by Hahn et al. that described creating human tumour cells with defined genetic elements. The notice flags a potential duplication of two bands in Figure 1b and acknowledges that...
Accelerated Intermittent Theta Burst Stimulation Targeting Personalized Fronto-Parietal Control Network Improves Core Symptoms of Autism Spectrum Disorder: A Double-Blind, Randomized...
A double‑blind, randomized trial evaluated a 12‑week accelerated intermittent theta‑burst stimulation (iTBS) protocol that targeted each participant’s fronto‑parietal control network using individualized functional MRI maps. Among 57 severely affected individuals with autism spectrum disorder, 55% of the active iTBS group...
Plasma P-Tau217 Tracks Alzheimer’s Biomarkers Over Time
A multi‑center longitudinal study shows that plasma p‑tau217 reliably tracks core Alzheimer’s disease biomarkers over time. Researchers measured p‑tau217 in blood samples from 1,200 participants and compared the results with amyloid PET scans and cerebrospinal fluid tau levels across a...
Psoriasis Paves the Way for Next-Generation TYK2 Inhibitors in Autoimmunity
Takeda and Alumis reported Phase III data for their next‑generation TYK2 inhibitors, zasocitinib and envudeucitinib, showing more than half of patients achieve PASI 90 in plaque psoriasis. The results close the efficacy gap between oral agents and injectable biologics, surpassing the 28%...
Vivici Sees 30% Boost in Titers, Yield, via Cell Productivity Tech From Enduro Genetics
Vivici, a precision‑fermentation startup producing whey beta‑lactoglobulin, integrated Enduro Genetics' Enduro Sense plug‑in into its production strain. Within five months the technology delivered a 30% lift in both titers and yields while using the same feedstock and bioreactor setup. The...
Phospholipid Asymmetry Helps Explain Extracellular Vesicle Surface Charge and Therapeutic Quality
Researchers led by Naohiro Seo and Takanori Ichiki published a review in ACS Nano Medicine that links extracellular vesicle (EV) surface charge to phospholipid asymmetry, especially the distribution of phosphatidylserine (PS). They show exosomes retain PS on the inner leaflet,...
CAR T Cell Therapy Biomanufactured by Cellares Infused Into First Two Patients
Cellares has successfully infused the first two patients with rese‑cel, Cabaletta Bio’s investigational autologous CAR‑T therapy, using its automated Cell Shuttle manufacturing platform. The product met all GMP release criteria, demonstrating that a low‑cost, high‑capacity process can produce clinical‑grade cell...
C-TRACT: Iliac Vein Stenting Results Look Good in Postthrombotic Syndrome
The C‑TRACT trial showed that adding iliac vein stenting to standard therapy markedly improves symptoms and quality of life for patients with post‑thrombotic syndrome after deep‑vein thrombosis. At six months, stented patients scored two points lower on the Venous Clinical...
Adcendo Raises $75M to Advance Cancer Drug Pipeline
Adcendo, a Copenhagen‑Boston biotech focused on antibody‑drug conjugates (ADCs), announced a $75 million Series C financing led by Jeito Capital. The capital will accelerate Phase 1 trials for three lead ADC candidates targeting tissue factor, uPARAP, and a preclinical asset. The round attracted...
CDER SBIA Chronicles
The FDA’s CDER Small Business & Industry Assistance (SBIA) Chronicles newsletter delivers regulatory guidance to drug manufacturers through a series of podcasts and a searchable archive. The most recent episodes—released on Dec 13 2024, Nov 14 2024, and May 17 2024—cover centralized statistical monitoring for data...
Pharmacy's Rising Role in Cell and Gene Therapy: Zahra Mamoudjafari, PharmD, MBA
Cell and gene therapies (CGTs) are receiving approvals faster than health‑care institutions can operationalize them. Zahra Mahmoudjafari, a clinical pharmacy leader at the University of Kansas Health System, published a framework outlining eight interdependent domains needed for financially sustainable, patient‑accessible...
Helpful Webinars and Other Resources for Generic Drug Manufacturers
The FDA has compiled a suite of webinars, workshops and seminars aimed at helping generic drug manufacturers improve their abbreviated new drug application (ANDA) submissions. Topics span bioequivalence studies, inactive ingredient databases, sample retention, and product‑specific challenges for oral, inhalation,...
About the Quantitative Medicine Center of Excellence (QM CoE)
The FDA’s Center for Drug Evaluation and Research (CDER) has launched the Quantitative Medicine Center of Excellence (QM CoE) to centralize quantitative expertise across its offices. Governance includes senior leaders from the Offices of Generic Drugs, New Drugs, Pharmaceutical Quality,...
FDA Clears Next-Gen Device for Left-Heart Access
Protaryx Medical received FDA clearance for its next‑generation Transseptal Puncture Device, enabling left‑heart access in minimally invasive cardiac procedures. The system features zero‑exchange delivery, an atraumatic design, an echogenic extendable probe and a standardized RF guidewire compatible with multiple electrosurgical...
Cancer Dependency Map Consortium Launches Phase 3 to Accelerate Next-Generation Therapeutics
The Broad Institute’s Cancer Dependency Map Consortium (DMC) has entered Phase 3, expanding its mission beyond cataloguing tumor vulnerabilities to tackling drug resistance, surface‑protein targets, and high‑dimensional readouts. Backed by 23 pharma partners, the consortium builds on DMC 2.0’s expansion to over...
Elahere Combination Achieves 62.7% ORR in Phase 2 Trial for Platinum-Sensitive Ovarian Cancer at SGO 2026
AbbVie’s Elahere (mirvetuximab soravtansine) combined with carboplatin produced a confirmed objective response rate of 62.7% in patients with FRα‑positive, platinum‑sensitive ovarian cancer, meeting the primary endpoint of the Phase 2 IMGN853‑0420 trial presented at SGO 2026. The study enrolled 125 participants,...
Enhancement of Intestinal Barrier Function and Alleviation of Mycophenolic Acid Toxicity by a Probiotic-Conditioned Medium in Vitro
The study demonstrates that an acellular probiotic‑conditioned medium (postbiotic) strengthens intestinal barrier function and mitigates toxicity of the immunosuppressants mycophenolic acid (MPA) and mycophenolate mofetil (MMF) in a CaCo‑2 cell model. The conditioned medium increased transepithelial electrical resistance, up‑regulated tight‑junction...
Regulation of Bile Acids Homeostasis: A Feasible and Versatile Way to Treat or Diagnose Liver Disorders
The review underscores bile‑acid (BA) homeostasis as a central driver of liver disease, linking imbalances to cholestasis, fibrosis, cirrhosis, hepatocellular carcinoma and MASLD/MASH. It details how hydrophobic BAs provoke mitochondrial and endoplasmic reticulum stress, activate hepatic stellate cells, and interact...
GLP-1 Drug Improves Liver Health Independent of Weight Loss, Mouse Study Finds
Researchers at Toronto’s Sinai Health discovered that semaglutide, a GLP‑1 agonist, improves liver function by acting directly on liver sinusoidal endothelial cells, independent of weight loss. The study, published in Cell Metabolism, used mouse models of metabolic dysfunction‑associated steatohepatitis (MASH)...
FDA Bolsters Bespoke Therapy Framework with New Draft Safety Guidelines
The FDA’s Center for Biologics Evaluation and Research issued draft guidance to standardize safety assessments for genome‑editing therapies, covering both ex vivo and in vivo products that use next‑generation sequencing to detect off‑target effects. The recommendations target nonclinical studies supporting IND and...
New Alzheimer’s Blood Test Promises Earlier Detection
Researchers at Mass General Brigham have shown that the blood‑based pTau217 biomarker can predict amyloid and tau plaque buildup years before PET scans turn positive, even in asymptomatic adults aged 50 to 90. The study of 317 participants demonstrated that...
Reproxalap Safe for Use in Patients With Dry Eye Disease
A Phase 3 trial of 0.25 % reproxalap eye drops in 757 dry‑eye disease patients found no serious treatment‑related adverse events. Mild ocular irritation was the most common side effect, occurring more often in older women. Visual acuity showed modest improvement, especially...
AWS Launches Amazon Bio Discovery for AI-Powered Scientific Experimentation
Amazon Web Services unveiled Amazon Bio Discovery, a cloud‑based platform that supplies scientists with a curated library of biological foundation models (bioFMs) for generating and evaluating drug molecules. The service lets researchers train custom models on their own experimental data...
Updated: FDA Asks for Data on Lilly’s Foundayo to Assess Heart, Liver Risks
The U.S. Food and Drug Administration has asked Eli Lilly for additional safety data on its newly approved obesity medication, Foundayo. The agency is specifically seeking information on any cardiovascular events and liver‑related adverse effects observed in clinical trials and post‑marketing...
Replimune Looks Ahead as Repeat CRL Speeds the Company's Decline
Replimune received a second complete response letter (CRL) from the FDA for its lead oncolytic cancer therapy, citing additional data gaps and manufacturing concerns. The regulatory setback triggered a wave of layoffs affecting roughly 30% of its workforce and pushed...
Two Previously Unreported Prostate Cancer Gene Candidates Identified Through Governed Multi-Omics Screening of TCGA-PRAD
A governed multi‑omics screening pipeline applied to the TCGA‑PRAD cohort filtered 19,010 genes through four independent quality gates, identifying 942 high‑confidence candidates. Ten matched known prostate cancer genes, confirming sensitivity, while two novel candidates—DNAH5 and PRR36—showed strong over‑expression and statistical...
Max Hodak’s Science Corp. Is Preparing to Place Its First Sensor in a Human Brain
Science Corp, the neurotechnology startup founded by former Neuralink president Max Hodak, has recruited Yale neurobiologist Murat Günel as a scientific adviser to oversee its first U.S. human trials of a bio‑hybrid brain‑computer interface. The company recently closed a $230 million Series C...
Novo Nordisk, OpenAI Bring AI Into Core Operations to Accelerate Time to Market
Novo Nordisk has teamed up with OpenAI to embed advanced artificial intelligence across its entire value chain, from early‑stage research to manufacturing, distribution, and commercial operations. The partnership aims to accelerate drug discovery, streamline production, and shorten the time it...
